Introduction
There is no doubt that cells of the adaptive immune system, both T and B-cells, are the central players of the graft rejection. However, elements of the innate immune system also play an important role in the initiation of early inflammatory responses and in the modulation of the graft rejection. Complement is a key component of innate immune system, presented in the plasma that participates in graft rejection.
The complement system is an integral part of the immune response and acts as a bridge between innate and acquired immunity. 1 
2.
Biologic activities of ficolin-3
The complement system has an essential role in antibodymediated kidney rejection via the classical C1q-dependent pathway. Deposition of downstream complement component i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 1 6 4 -1 6 7 a r t i c l e i n f o factor C4 is a prognostic marker of reduced long-term graft survival. 2, 3 There are three known pathways for complement activation: classical, alternative and lectin pathways ( Fig. 1 ). Forty years after the proposal of the alternative pathway, the MBL (mannose-binding lectin)/MASP (MBL-associated serine protease) pathway was discovered. This pathway was characterized by using proteins isolated from rabbit liver and serum, but its function remained unclear initially. The initiating molecules for this pathway are collectins (MBL and ficolin), which are ultimeric lectin complexes. These bind to specific carbohydrate patterns uncommon in the host, leading to activation of the pathway through enzymatic activity of MASP.
There are structural similarities shared between MBL and C1 complexes (MBL-with C1q-associated serine proteases, MASP-1 and MASP-2 with C1r and C1s, respectively), leading to the belief that complement activation by MBL and C1 complexes is similar. MASP-2 cleaves C4 and C2 to form C3 convertase, while MASP-1 may cleave C3 directly bypassing the C4b2a complex, albeit at a very slow rate. Another serine protease, MASP-3 was shown to downregulate the C4 and C2 cleaving activity of MASP-2. Unlike pigs or mice, humans have three ficolins, all of which are present in the bloodstream: M-ficolins (monocyte ficolin or ficolin-1); L-ficolin (liver ficolin or ficolin-2); and H-ficolin (Hakata antigen or ficolin-3). M-and L-ficolins have 80% identity in amino acid sequence; H-ficolin has only about 50% identity with the other two. M-ficolin, predominantly found in monocytes and granulocytes, is the homologue of murine ficolin-B and porcine ficolin-b; L-ficolin is the homologue of murine ficolin-A and porcine ficolin-a. The third human ficolin, the Hakata antigen originally identified and defined by autoantibodies present in a small minority of lupus patients, is synthesized in both liver (secreted into bile as well as blood) and lung (and secreted into the bronchi). It is the most abundant plasma ficolin and the most potent at activating complement in vitro. 4 Comparative study by Hummelshoj revealed that FCN3 mRNA was highly expressed in the liver and lung compared with the other genes revealing the lung as the tissue with the highest FCN3 expression pattern. Ficolin-3 revealed higher complement activating capacity compared with ficolin-2, MBL and ficolin-1 and was highly resistant to bacterial collagenase treatment, which is different from the other ficolins and MBL. Moreover, ficolin-3 has a high complement activating potential and is the only collagenase proteolytic resistant molecule among the lectin complement pathway initiators. 5 Ficolin-3 is the most abundant recognition molecule of the lectin pathway with a plasma concentration around 18.4 mg/ ml, varying 10-fold among individuals (3-54 mg/ml). Ficolin-3 was found highly expressed in the liver and lung tissues, indicating its significance in both activation of the lectin pathway and pulmonary host defense. For that reason, ficolin-3 is considered to play an important role in both systemic and local innate immune responses.
Ficolin-3 was shown to recognize acetyl groups present in a wide range of micro-organisms, including Salmonella typhimurium, Salmonella minnesota, Escherichia coli and Aerococcus viridians. It was also shown to share binding sites with ficolin-2 and MBL on the surface of Giardia intestinalis. Furthermore, ficolin-3 may mediate the clearance of late apoptotic cells and may have a beneficial role against autoimmunity. 6 Study by Honoré et al. demonstrated the role ficolin-3 as a direct opsonin of late apoptotic cells, where ficolin-3 binds to the dying cells through the fibrinogen like domain of the molecule and interacts with receptors on the phagocytes, presumably through the collagen-like domain. It appears that ficolin-3 is a much more powerful direct opsonin than is ficolin-2. Ficolin-3 is thought to play an antiinfectious role in host defense. The present results suggest an additional role for ficolin-3 and place the molecules on the interface between internal tissue homeostasis and innate immunity. Studies by Chen et al. investigated serum ficolin-3 levels in association with insulin resistance and predict the incidence of T2DM. They demonstrated that decreased serum ficolin-3 was independently correlated with insulin resistance and low serum ficolin-3 predicted the development of T2DM. 7 Nevertheless, a recent study implies that ficolin-3 may not always be beneficial, since activation of the lectin complement pathway by ficolin-3 was associated with C4 deposition in the peritubular capillaries of kidney allografts. 8 Thus, a dual role of ficolin-3 may be suggested, one being beneficial, while the other unfavorable effect, which does not result in bacterial or cellular clearance, may lead to uncontrolled complement activation, resulting in adverse effects on the host (Fig. 2) . 9 
Ficolin-3 in kidney graft loss
The development of a reliable C4d immunostaining technique in 1991 was a major advance in this research area, as it provided indirect evidence of donor specific antibodies (DSA) binding to the allograft and suggested a role for complement activation in antibody-mediated rejection (AMR). 10 Because ficolin-3 has been shown to be deposited along with C4d in kidney allograft suggesting that additional mechanisms other than antibody mediated activation may lead to C4 deposition and downstream complement activation associated with inflammation and tissue damage. Bay et al. hypothesized that ficolin-3 might be one of the initiating factors involved in kidney rejection. Using a prospective study design, 527 kidney transplanted patients were included. A total of 97 blood donors served as controls. Ficolin-3, C4, and C3 were measured in pretransplant as well as in control serum samples. In controls, deposition of ficolin-3, C4, C3 and the terminal complement complex (TCC) was measured in an assay based on acetylated albumin as matrix. The ficolin-3 levels correlated with the serum levels of C4 and C3. The serum levels of ficolin-3 correlated with the deposition of ficolin-3, C4, C3 and TCC. This study supports that ficolin-3 may participate in kidney graft rejection. The observed correlation between ficolin-3 and deposition of downstream C4, C3 and formation of TCC indicates that the ficolin-3 dependent complement pathway may be a feasible tool for therapeutic intervention in kidney graft rejection. 11 Another study by Smedbraten et al. performed retrospective study was to assess the impact of the pattern recognition molecules of the lectin pathway on long-term graft survival after kidney transplantation. Mannose-binding lectin, ficolin-1, and ficolin-3 were measured in serum at the time of transplantation. A total of 382 patients with a median followup of 9.8 years were included. Sixty-six patients (17%) had death censored graft loss, and 116 (30%) patients died. In a final competing risks model, high ficolin-3, acute rejection, and age were associated with death-censored graft loss. Basiliximab induction was associated with improved graft survival. No associations between mannose-binding lectin or ficolin-1 and graft loss were found. In conclusion, a high ficolin-3 level at the time of transplantation was an independent significant risk factor for shorter graft survival, even when adjusting for other covariates. 12 
Conclusion
In conclusion, serum complement cascade, a part of innate immunity required for host protection against invading pathogens, is also a mediator of various forms of disease and injury. The role the complement system activation in kidney transplant setting is through tailoring the tissue inflammation and recipient alloimmunity. There is still a need to look for new methods diagnosing renal rejection, which are less invasive than graft biopsy. It seems that serum ficolin-3 may be a diagnostic feasible tool for kidney rejection that needs to have further studies.
